These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 20400201)

  • 1. Randomized phase II trial of gefitinib or gemcitabine or docetaxel chemotherapy in patients with advanced non-small-cell lung cancer and a performance status of 2 or 3 (IFCT-0301 study).
    Morère JF; Bréchot JM; Westeel V; Gounant V; Lebeau B; Vaylet F; Barlési F; Urban T; Souquet PJ; Debieuvre D; Baudrin L; Zalcman G; Morin F; Milleron B; Moro-Sibilot D
    Lung Cancer; 2010 Dec; 70(3):301-7. PubMed ID: 20400201
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Similar survival rates with first-line gefitinib, gemcitabine, or docetaxel in a randomized phase II trial in elderly patients with advanced non-small cell lung cancer and a poor performance status (IFCT-0301).
    Des Guetz G; Landre T; Westeel V; Milleron B; Vaylet F; Urban T; Barlesi F; Souquet PJ; Debieuvre D; Braun D; Fraboulet G; Monnet I; Uzzan B; Molinier O; Morin F; Moro-Sibilot D; Morère JF
    J Geriatr Oncol; 2015 May; 6(3):233-40. PubMed ID: 25698450
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomised multicenter phase II study of two schedules of docetaxel and gemcitabine or cisplatin/gemcitabine followed by docetaxel as first line treatment for advanced non-small cell lung cancer.
    Novello S; Falcone A; Crinò L; Rinaldi M; Nardi M; De Marinis F; Tonato M; Tibaldi C; Tinazzi A; Russo F; Grassivaro N; Scagliotti GV
    Lung Cancer; 2009 Dec; 66(3):327-32. PubMed ID: 19329221
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1.
    Giaccone G; Herbst RS; Manegold C; Scagliotti G; Rosell R; Miller V; Natale RB; Schiller JH; Von Pawel J; Pluzanska A; Gatzemeier U; Grous J; Ochs JS; Averbuch SD; Wolf MK; Rennie P; Fandi A; Johnson DH
    J Clin Oncol; 2004 Mar; 22(5):777-84. PubMed ID: 14990632
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized phase II study comparing weekly docetaxel-cisplatin vs. gemcitabine-cisplatin in elderly or poor performance status patients with advanced non-small cell lung cancer.
    Jang J; Kim HK; Cho BC; Lee KH; Yun HJ; Woo IS; Song HS; Ryoo HM; Kim CH; Sun DS; Shin JW
    Cancer Chemother Pharmacol; 2017 May; 79(5):873-880. PubMed ID: 28341958
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Salvage therapy for Chinese non-small cell lung cancer patients who failed previous chemotherapy.
    Chen YM; Perng RP; Shih JF; Tsai CM; Whang-Peng J
    J Thorac Oncol; 2006 Jul; 1(6):545-50. PubMed ID: 17409915
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gemcitabine and vinorelbine followed by weekly docetaxel in patients with advanced non-small-cell lung cancer: a phase II trial of sequential chemotherapy.
    Cobo Dols M; Villar Chamorro E; Alés Díaz I; Gil Calle S; Alcalde García J; Gutiérrez Calderón V; Carabantes Ocón F; Montesa Pino A; Bretón García JJ; Benavides Orgaz M
    Clin Transl Oncol; 2006 Oct; 8(10):742-9. PubMed ID: 17074673
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II, open-label, randomized study (SIGN) of single-agent gefitinib (IRESSA) or docetaxel as second-line therapy in patients with advanced (stage IIIb or IV) non-small-cell lung cancer.
    Cufer T; Vrdoljak E; Gaafar R; Erensoy I; Pemberton K;
    Anticancer Drugs; 2006 Apr; 17(4):401-9. PubMed ID: 16549997
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase II study of days 1 and 8 combination of docetaxel plus gemcitabine for the second-line treatment of patients with advanced non-small-cell lung cancer and good performance status.
    Cobo M; Gutiérrez V; Alcaide J; Alés I; Villar E; Gil S; Durán G; Martínez J; Carabantes F; Bretón JJ; Benavides M
    Lung Cancer; 2007 May; 56(2):255-62. PubMed ID: 17276537
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemotherapy effectiveness after first-line gefitinib treatment for advanced lepidic predominant adenocarcinoma (formerly advanced bronchioloalveolar carcinoma): exploratory analysis of the IFCT-0401 trial.
    Duruisseaux M; Baudrin L; Quoix E; Wislez M; Moro-Sibilot D; Coëtmeur D; Monnet I; Mourlanette P; Morère JF; Soria JC; Westeel V; Morin F; Cadranel J
    J Thorac Oncol; 2012 Sep; 7(9):1423-31. PubMed ID: 22767177
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.
    Rosell R; Carcereny E; Gervais R; Vergnenegre A; Massuti B; Felip E; Palmero R; Garcia-Gomez R; Pallares C; Sanchez JM; Porta R; Cobo M; Garrido P; Longo F; Moran T; Insa A; De Marinis F; Corre R; Bover I; Illiano A; Dansin E; de Castro J; Milella M; Reguart N; Altavilla G; Jimenez U; Provencio M; Moreno MA; Terrasa J; Muñoz-Langa J; Valdivia J; Isla D; Domine M; Molinier O; Mazieres J; Baize N; Garcia-Campelo R; Robinet G; Rodriguez-Abreu D; Lopez-Vivanco G; Gebbia V; Ferrera-Delgado L; Bombaron P; Bernabe R; Bearz A; Artal A; Cortesi E; Rolfo C; Sanchez-Ronco M; Drozdowskyj A; Queralt C; de Aguirre I; Ramirez JL; Sanchez JJ; Molina MA; Taron M; Paz-Ares L;
    Lancet Oncol; 2012 Mar; 13(3):239-46. PubMed ID: 22285168
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination second-line chemotherapy with gemcitabine and docetaxel for recurrent non-small-cell lung cancer after platinum-containing chemotherapy: a phase I/II trial.
    Niho S; Kubota K; Goto K; Ohmatsu H; Matsumoto T; Kakinuma R; Nishiwaki Y
    Cancer Chemother Pharmacol; 2003 Jul; 52(1):19-24. PubMed ID: 12712259
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomised phase II trial of two sequential schedules of docetaxel and cisplatin followed by gemcitabine in patients with advanced non-small-cell lung cancer.
    Grossi F; de Marinis F; Gebbia V; Riccardi F; Caffo O; Gamucci T; Ferraù F; Nardi M; Moscetti L; Boni L; Dondi D; Galligioni E
    Cancer Chemother Pharmacol; 2012 Feb; 69(2):369-75. PubMed ID: 21833588
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gemcitabine and docetaxel as second-line chemotherapy for patients with nonsmall cell lung carcinoma who fail prior paclitaxel plus platinum-based regimens.
    Kosmas C; Tsavaris N; Vadiaka M; Stavroyianni N; Koutras A; Malamos N; Onyenadum A; Rokana S; Polyzos A; Kalofonos HP
    Cancer; 2001 Dec; 92(11):2902-10. PubMed ID: 11753965
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Docetaxel plus gemcitabine versus gemcitabine in elderly patients with advanced non-small cell lung cancer and use of a geriatric assessment: Lessons from a prematurely closed Hellenic Oncology Research Group randomized phase III study.
    Karampeazis A; Vamvakas L; Kotsakis A; Christophyllakis C; Kentepozidis N; Chandrinos V; Agelidou A; Polyzos A; Tsiafaki X; Hatzidaki D; Georgoulias V
    J Geriatr Oncol; 2017 Jan; 8(1):23-30. PubMed ID: 27264267
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of pemetrexed as second-line therapy in advanced NSCLC after either treatment-free interval or maintenance therapy with gemcitabine or erlotinib in IFCT-GFPC 05-02 phase III study.
    Bylicki O; Ferlay C; Chouaid C; Lavolé A; Barlési F; Dubos C; Westeel V; Créquit J; Corre R; Vergnenègre A; Monnet I; Le Caer H; Fournel P; Vaylet F; Falchero L; Poudenx M; Linard P; Pérol D; Zalcman G; Pérol M
    J Thorac Oncol; 2013 Jul; 8(7):906-14. PubMed ID: 23591160
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase 2 trial of docetaxel and gefitinib in the first-line treatment of patients with advanced nonsmall-cell lung cancer (NSCLC) who are 70 years of age or older.
    Simon GR; Extermann M; Chiappori A; Williams CC; Begum M; Kapoor R; Haura EB; Ismail-Khan R; Schell MJ; Antonia SJ; Bepler G
    Cancer; 2008 May; 112(9):2021-9. PubMed ID: 18300255
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vinorelbine plus gemcitabine followed by docetaxel versus carboplatin plus paclitaxel in patients with advanced non-small-cell lung cancer: a randomised, open-label, phase III study.
    Kubota K; Kawahara M; Ogawara M; Nishiwaki Y; Komuta K; Minato K; Fujita Y; Teramukai S; Fukushima M; Furuse K;
    Lancet Oncol; 2008 Dec; 9(12):1135-42. PubMed ID: 19013107
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Docetaxel/gemcitabine or cisplatin/gemcitabine followed by docetaxel in the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC): results of a multicentre randomized phase II trial.
    Binder D; Schweisfurth H; Grah C; Schäper C; Temmesfeld-Wollbrück B; Siebert G; Suttorp N; Beinert T
    Cancer Chemother Pharmacol; 2007 Jun; 60(1):143-50. PubMed ID: 17031643
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sequential administration of vinorelbine plus cisplatin and bevacizumab followed by docetaxel plus gemcitabine and bevacizumab compared to docetaxel plus cisplatin and bevacizumab regimen as first-line therapy for advanced or metastatic non-squamous non-small cell lung cancer: A multicenter randomized phase II trial of the Hellenic Oncology Research Group (HORG).
    Kotsakis A; Kentepozidis N; Emmanouilidis Ch; Polyzos A; Agelidou A; Vaslamatzis M; Chandrinos V; Agelaki S; Vamvakas L; Kalbakis K; Katsaounis P; Stoltidis D; Nintos G; Hatzidaki D; Vetsika EK; Mavroudis D; Georgoulias V
    Lung Cancer; 2015 Apr; 88(1):57-62. PubMed ID: 25662596
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.